News from celsion corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

08:00 ET

Celsion to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

 Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion's Chairman,...

Aug 10, 2015, 08:30 ET

Celsion and myTomorrows Expand ThermoDox® European Early Access Program to Include Patients with Primary Liver Cancer and Liver Cancer Metastases

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that it has expanded its Early Access Program (EAP) for...

Aug 10, 2015, 08:00 ET

Celsion Corporation Reports Second Quarter 2015 Financial Results and Provides Business Update

 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended June 30,...

Aug 07, 2015, 06:22 ET

Celsion Corporation anuncia los datos de supervivencia general actualizados del estudio HEAT de ThermoDox®

- Celsion Corporation anuncia los datos de supervivencia general actualizados del estudio HEAT de ThermoDox® en cáncer hepático...

Aug 06, 2015, 19:38 ET

Celsion Corporation veröffentlicht aktualisierte Gesamtüberlebensdaten aus der HEAT-Studie zu ThermoDox® bei primärem Leberkrebs

- Daten zeigen weiterhin eine statistisch bedeutende Verbesserung des Gesamtüberlebens in Form eines Überlebensvorteils von mehr als 2...

Aug 06, 2015, 12:25 ET

Celsion Corporation annonce des données mises à jour sur la survie brute obtenues par l'étude HEAT portant sur ThermoDox® pour le cancer primitif du foie

- Les données continuent à montrer une amélioration statistiquement significative de la survie brute, ce qui se traduit par un...

Aug 06, 2015, 08:00 ET

Celsion Corporation Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer

 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced updated results from its retrospective analysis of...

Aug 03, 2015, 08:00 ET

Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015

 Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its second quarter 2015 financial...

Jul 06, 2015, 08:00 ET

Celsion Announces Continuing Positive Data from Its Phase 2 DIGNITY Study in Breast Cancer

Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox®...

Jul 01, 2015, 08:00 ET

Celsion Corporation to Present at Cantor Fitzgerald's Inaugural Healthcare Conference on July 8, 2015

 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael H. Tardugno, Chairman, President and...

Jun 01, 2015, 08:00 ET

Celsion Presents GEN-1 Immunotherapy Phase 1b Results in Recurrent Ovarian Cancer at ASCO 2015

Celsion Corporation (NASDAQ: CLSN), a fully integrated oncology drug development company, announced the presentation of clinical results from its...

May 28, 2015, 08:45 ET

Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering

Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has received commitments from two institutional healthcare investors to...

May 21, 2015, 08:00 ET

Celsion Announces Potent, Durable Preclinical Lung Expression Data for Its Novel TheraSilence™ RNA Program

 Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer...

May 15, 2015, 08:00 ET

Celsion Announces Publication of Preclinical Data Demonstrating Lung Specific Delivery of microRNA-145 Inhibitor Using Its Novel TheraSilence™ Platform

Celsion Corporation (NASDAQ:CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer...

May 13, 2015, 17:01 ET

Celsion Corporation Announces ASCO 2015 GEN-1 Immunotherapy Phase 1b Results in Ovarian Cancer Presentation

 Celsion Corporation (NASDAQ: CLSN), a fully integrated oncology drug development company, today announced that results from its Phase Ib trial...

May 12, 2015, 08:00 ET

Celsion Corporation Reports First Quarter 2015 Financial Results and Provides Business Update

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2015...

May 05, 2015, 08:00 ET

Celsion Corporation to Hold First Quarter 2015 Financial Results Conference Call on Tuesday, May 12, 2015

 Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its first quarter 2015 financial...

Apr 29, 2015, 08:00 ET

Celsion Expands Clinical Development Plan for GEN-1 IL-12 Immunotherapy Program in Ovarian Cancer

 Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer...

Apr 27, 2015, 08:00 ET

Celsion Corporation Announces Appointment of Harriet Shelare to Director, Communications

 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the appointment of Harriet Shelare as Director,...

Apr 15, 2015, 08:00 ET

Celsion Announces Positive Interim Data from its Phase 2 DIGNITY Study in Breast Cancer

 Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox®...